Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor.

Despite the China worries, Gardasil has become a key product for Merck. After growing more than ... Davis’ $10.8 billion ...

Merck (NYSE:MRK) announced the opening of a new $1 billion vaccine manufacturing facility in Durham, North Carolina, a major development aligning with the company's broader $12 billion U.S. investment ...

Merck has taken steps in mergers and acquisition to diversify its pipeline and product offerings, including the $10.8 billion acquisition of Prometheus Biosciences and a major licensing deal with ...

Merck & Co has reached an agreement to buy Prometheus Biosciences in a $200-per-share ... PRA023 had the potential to be a “pipeline in a product”. Meanwhile, following after PRA023 is PRA052 ...

The company has made moves in the oncology space in recent years, including an October 2024 acquisition of Modifi Biosciences ... up to $1.3bn. Merck KGaA’s top-selling product in 2024 was ...

Merck & Co has continued to bolster its pipeline with smaller deals – with its latest a $1.35 billion agreement to buy Imago BioSciences and its bomedemstat drug candidate for blood disorders.

The company operates as EMD Biosciences, Inc. in North America and as Merck Biosciences outside ... grown with Overnight Express System 2. a The products and technologies presented in this article ...